Introduction: LN is a serious complication of juvenile SLE . Previous studies have suggested a role for toll-like receptor 7 (TLR7) and TLR9 in SLE pathogenesis. Podocytes are specialized cells in the glomerular filtration barrier. Biopsies from LN patients have demonstrated higher TLR7 and TLR9 expression in glomeruli compared with controls. Aims: To examine the role of TLR7 and TLR9 in podocytes to identify potential targets for more effective therapies of LN. Method: Conditionally immortalized human podocytes were cultured. Quantitative PCR and Western blotting were used to detect TLR7 and TLR9 expression at the mRNA and protein level respectively. The effects of lipopolysaccharide (LPS), an inflammatory stimulus, imiquimod (TLR7 agonist), CpG (TLR9 agonist) and dexamethasone were examined. Phosphorylation of NFkB was assessed with Western blotting and a cell proliferation assay used to estimate cell survival. Introduction: Paediatric rheumatic diseases (PRDs) comprise JIA, childhood-onset SLE, APS, vasculitis, scleroderma, JDM and periodic fever syndromes. They are rare conditions with significant morbidity. Due to their low incidence, treatment is insufficiently based on evidence and management differs throughout Europe. In order to guarantee optimal care there is a need for standardized management plans for children with PRD in Europe. Aims: As a part of SHARE (Single Hub and Access Point for Paediatric Rheumatology in Europe), a work package (WP5) has been defined to identify best practice and establish minimal standards of care for the treatment of patients with PRDs, in order to improve and standardize care across Europe. Method: A systematic review was conducted on specific questions regarding diagnosis, treatment and complications of PRD. MEDLINE, EMBASE and Cochrane were searched using systematically built and validated search strings. After screening, a review process will be executed according to EULAR guidelines by groups of experts from PReS workgroups. The EULAR method for achieving recommendations guidelines on treatment of patients were followed. Results: The results from the systematic reviews will be discussed in consensus meetings. Guidelines will be finalized by defining gaps in knowledge and adding expert opinion, using the Delphi method. This will lead to the formulation of minimum standards of care for individual PRDs. Conclusion: It is essential to formulate well-founded standards of care for these rare paediatric diseases; doing so will most importantly benefit patients themselves, but also increase uniformity of care within the European Union. Table 1 ). Results: Table 1 summarizes the anticipated WP goals and outcomes. Specifically, WP4 is identifying specific needs for optimal care in PRD in all European countries. All centres and individual experts in PRD within each centre will receive questionnaires regarding Conclusion: SHARE will set international standards to present to health authorities, PRD centres, health care insurance companies and patient/parent organizations. Disclosure statement: The authors have declared no conflicts of interest. 
